StockNews.AI
BLTE
StockNews.AI
161 days

Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

1. Belite Bio plans a webcast on March 17 for financial results. 2. The company focuses on treatments for degenerative retinal diseases. 3. Lead candidate Tinlarebant is in Phase 3 trials for STGD1 and GA. 4. Webcast will offer business updates for Q4 and full year 2024. 5. Replay of the webcast will be available for 90 days post-event.

Earnings
+2.48%Current Return
VS
-0.83%S&P 500
$66.9503/11 03:14 AM EDTEvent Start
$68.6103/12 09:26 AM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming webcast may boost investor confidence, especially if positive data is presented. Past similar announcements accompanied stock price increases in biotech firms.

How important is it?

The webcast on financial results can significantly impact investor perceptions and subsequent stock performance due to transparency and potential positive news.

Why Short Term?

Immediate market reactions typically follow financial disclosures and business updates. The webcast's timing aligns closely with upcoming earnings reports, likely to influence price soon.

Related Companies

AMGNREGNVRTXNVDAJNJ
March 11, 2025 03:00 ET  | Source: Belite Bio, Inc SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, March 17, 2025, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the fourth quarter and full year ended December 31, 2024. Webcast InformationDate: Monday, March 17, 2025Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)Webcast Link: https://events.q4inc.com/attendee/481614529 Webcast Link InstructionsYou can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events. A replay will be available for approximately 90 days after the event. About Belite BioBelite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com. Media and Investor Relations Contact:Jennifer Wu ir@belitebio.com Julie Fallonbelite@argotpartners.com

Related News